l-Arginine treatment for severe vascular fetal intrauterine growth restriction: A randomized double-bind controlled trial

Winer, Norbert; Branger, B.; Azria, Élie; Tsatsaris, Vassilis; Philippe, Henri-Jean; Rozé, Jean‐Christophe; Descamps, Philippe; Georges, B; Cynober, Luc; Darmaun, Dominique

doi:10.1016/j.clnu.2009.03.007

Cited by 48 publications

(42 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were presented by Lampariello et al [22]. However, in another study Winer et al [23] reported no significance difference among the group supplemented with arginine compare to control group.…”

Section: Discussionsupporting

confidence: 90%

Effect of l-Arginine on Nitric Oxide Levels in Intrauterine Growth Restriction and its Correlation with Fetal Outcome

Singh

Sharma

et al. 2014

Ind J Clin Biochem

View full text Add to dashboard Cite

The current management of intrauterine growth restriction (IUGR) being empirical and aimed at selecting a safe time for delivery. Acknowledging the beneficial effects of l-arginine on endothelial vasculature the present study was designed to evaluate efficacy of l-arginine on bioavailability of nitric oxide (NO) with respect to fetal outcome. With l-arginine supplementation, mean NO levels were significantly increased and a significant mild reduction in systolic/end-diastolic velocity ratio (S/D ratio) was observed on doppler blood flow study, also neonatal outcome improved and incidences of complications were lowered. A deficiency in NO may play an important role in the causation of asymmetric fetal growth restriction. l-Arginine can be used to increase maternal NO levels, enhancing birth weight and decreasing neonatal morbidity. The ideal candidate for arginine therapy according to our study would be IUGR cases with S/D ratio less than 4.96 ± 0.49 and NO levels below 33 μmol/L with minimum of 3 weeks duration of arginine supplementation.

show abstract

Section: Discussionsupporting

confidence: 90%

Effect of l-Arginine on Nitric Oxide Levels in Intrauterine Growth Restriction and its Correlation with Fetal Outcome

Singh

Sharma

et al. 2014

Ind J Clin Biochem

View full text Add to dashboard Cite

show abstract

“…Sieroszewski et al (11) demonstrated that L-Arg administration to pregnant women with growth restriction may improve fetal growth and increase birth weight. However, the study performed by Winer et al (31) indicated that L-Arg was not an effective treatment for severe vascular growth restriction. In the present study, the effect of L-Arg supplementation in early postnatal rats on the hepatic PI3K signaling pathway and gluconeogenic enzymes was first examined.…”

Section: Discussionmentioning

confidence: 99%

Effect of L-arginine supplementation on the hepatic phosphatidylinositol 3-kinase signaling pathway and gluconeogenic enzymes in early intrauterine growth-restricted rats

Luo

Chen

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the response of the phosphatidylinositol 3-kinase (PI3K) signaling pathway and gluconeogenic enzymes in intrauterine growth-restricted rats to dietary L-arginine (L-Arg) supplementation during the lactation period early in life. Pregnant Sprague-Dawley rats were randomly divided into a control group (CON), an intrauterine growth restriction group (IUGR) and an L-Arg group (LA). The pregnant rats in the CON group were fed a 21% protein diet, and those in the IUGR and LA groups were fed a 10% low protein diet, and all rats were fed a 21% protein diet after delivery. Water was available ad libitum to the pregnant rats during the 21-day lactation period, and the water provided to the LA group included 200 mg/kg/day L-Arg. Blood glucose, serum insulin, homeostasis model of assessment for insulin resistance (HOMA-IR), PI3K and protein kinase B (PKB) protein expression, and phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G-6-Pase) mRNA expression in the offspring rats were measured postnatally at 1, 3 and 8 weeks. No significant difference in blood glucose, serum insulin and HOMA-IR were identified at any time point among the three groups. PI3K and PKB expression was lower in the IUGR group offspring compared with that in the CON group offspring, but both were increased by dietary L-Arg supplementation. PEPCK mRNA and G-6-Pase mRNA expression levels in the offspring of the IUGR group were higher compared with those in the CON group but were downregulated following L-Arg supplementation. These results suggest that dietary L-Arg supplementation during the early lactation period promoted catch-up growth and reversed abnormalities in hepatic insulin signaling and gene expression of gluconeogenic enzymes in IUGR offspring rats.

show abstract

“…L-Arginine given to women with gestational hypertension, preeclampsia, or IUGR may lead to improved maternal BP and uteroplacental circulation [270][271][272][273][274][275] but dosage needs to be defined and large RCTs are required.…”

Section: Preventing Preeclampsia and Its Complications In Women At Inmentioning

confidence: 99%

RETIRED: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy

Magee

Pels

Helewa

et al. 2008

Journal of Obstetrics and Gynaecology Canada

421

218

View full text Add to dashboard Cite

l-Arginine treatment for severe vascular fetal intrauterine growth restriction: A randomized double-bind controlled trial

Cited by 48 publications

References 49 publications

Effect of l-Arginine on Nitric Oxide Levels in Intrauterine Growth Restriction and its Correlation with Fetal Outcome

Effect of l-Arginine on Nitric Oxide Levels in Intrauterine Growth Restriction and its Correlation with Fetal Outcome

Effect of L-arginine supplementation on the hepatic phosphatidylinositol 3-kinase signaling pathway and gluconeogenic enzymes in early intrauterine growth-restricted rats

RETIRED: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy

Contact Info

Product

Resources

About